We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.55% | 9.15 | 8.80 | 9.50 | 9.15 | 8.86 | 9.10 | 1,054,095 | 12:15:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.09 | 84.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/11/2017 14:44 | Tosh. Shameful words. Shameful. ''Just go away you horrible little man... you're worthless''. Shocking. Inanaco posts more 'on the button stuff' in one post than you have in 7 years. I used to read your LSE stuff and sometimes stick up for you. ''UNEDUCATED - LIAR - CHEAT - LOSER'' . . . maybe that's you M8 ! Maybe Inan ain't perfect but !! For God's sake. I don't know what your problem is but Good Luck with it ! Never seen so much anger. Are you still a holder ? If not, why not ? Take care. (btw he ain't a little man). Empty vessels make the most noise I'm told. Your analysis on Inan's 12148 is eagerly awaited. | torquayfan | |
01/11/2017 14:03 | any news on the 2013 trade sale ? | kreature | |
01/11/2017 13:58 | Inanaco, Thanks, yes, the link I posted was to the abstract, so I have read that but can't read the full research paper without paying. Believe the Enolase patent application was filed way back and we discussed it when it was published. | bermudashorts | |
01/11/2017 13:24 | Just go away you horrible little man... you're worthless. | tosh123 | |
01/11/2017 13:13 | TEA LEAF - YOU, as in keeping with YOUR *LIMITED level of intellect*, persist in exhibiting, via YOUR posts, the FAILURE to recognise,that,for YEARS, to many, many observers, YOUR posts CONtinue to fully CONtain, what is best described as - FULL OF * The word on the SEAT * | the real lozan | |
01/11/2017 13:09 | Ineptico, your posts over the years, if printed, would be suitable for any rubbish bin in the universe. Year in year out, you have called everything 100% wrong wrong wrong. You have proven yourself to be an UNEDUCATED - LIAR - CHEAT - LOSER at every stage of your posting history, who is now seen by many to be a single celled organism that should return to the rock, from which you crawled from under. Your credibility = zero. Now please crawl away. | tosh123 | |
01/11/2017 12:53 | Hi boom ref your 12146 as per AGM 2017 """ Patent filed on citrullinated enolase peptides for the treatment of cancer """ from your link i found the abstract. ABSTRACT Targeting post-translationally modified epitopes may provide a new strategy for generating tumor specific immune responses. Citrullination is the post-translational modification of arginine to citrulline catalyzed by peptidylarginine deaminase (PAD) enzymes. Presentation of citrullinated peptides on MHC-II has been associated with autophagy. Tumors upregulate autophagy and present citrullinated peptides in response to stresses including nutrient deprivation, oxygen deprivation, redox stress and DNA damage, making them good targets for immune attack. The ubiquitous glycolytic enzyme α-enolase (ENO1) is often citrullinated and degraded during autophagy. Immunization of mice with two citrullinated ENO1 peptides (ENO1 241–260cit253 or 11–25cit15) induced strong Th1 responses that recognize the post-translationally modified, but not the wild type unmodified epitope. ENO1 11–25cit15 induced tumor therapy of melanoma cells in C57░Bl/6 (B16F1 50% survival p = 0.0026) and ENO1 241–260cit253 in HLA-DR4 transgenic mice (B16-DR4 50% survival p = 0.0048). In addition, ENO1 241–260cit253 induced therapy of pancreatic (Pan02-DR4 50% survival p = 0.0076) and lung (LLC/2-DR4 40% survival p = 0.0142) tumors in HLA-DR4 transgenic mice. The unmodified epitope induced no anti-tumor response. Minimal regression of class II negative B16░or LLC/2 tumor was seen, confirming direct recognition of MHC-II was required. Most tumors only express MHC-II in the presence of IFNγ; an IFNγ inducible model showed strong responses, with rejection of tumors in up to 90% of animals (p = 0.0001). In humans, a repertoire to ENO1 241–260cit253 was observed in healthy donors. This response was CD4 mediated and seen in people with a variety of HLA types suggesting a broad application for this vaccine in human cancer therapy. Loz, your posts over the years if printed, would be suitable for Anaerobic digestion but i feel the bugs would get bored with the same recipe repeated year in, year out like the rest of us. | inanaco | |
01/11/2017 08:17 | I don't think I'm being too optimistic to expect something of significance from the EPO's publication of the Moditope Divisional application - a mere week away today ? Not sure what will be confirmed but at least we know some news WILL be coming. In the time honoured tradition - expect the unexpected ?! | gooosed | |
01/11/2017 08:16 | New research from Scancell has been published in the latest issue of OncoImmunology link below. Unfortunately you can't read the full paper without paying but you can get a taste. It's all about a-enolase, one of the citrullinated peptides selected for Modi1. | bermudashorts | |
01/11/2017 07:23 | Last time I heard the expression "word on the street" it was huggy bear on starskey and hutch. I must say I think huggy was a far more credible source of information. What say you commissioner? | gazza | |
01/11/2017 01:03 | Good Morning Lozan and of course I apologize for offending your well known and gentle sensibilities. In my defence, maybe I thought it unlikely that a 'casual observer' would be in possession of any crucial inside info. Regarding Fragma - C7 was spot on this time with his comment 'bullshoot'. However I'll pop you back on 'filter'. Nice day to you. | torquayfan | |
31/10/2017 20:45 | Bob 1 loz 0 usual result pundits view ... Loz has no street cred at all ... The village was boarded up as per photo | inanaco | |
31/10/2017 18:43 | yeah but I said it first :) | bermudashorts | |
31/10/2017 18:28 | BoB - I could say the same to you ??? | the real lozan | |
31/10/2017 18:04 | Loz, you are missing my point | bermudashorts | |
31/10/2017 17:23 | BoB On these forums, everyone is 'a casual observer' ONLY the trHYPE CLUB believe they are 'more credible' than anyone else THEY ARE NOT Quite the opposite.... in FACT | the real lozan | |
31/10/2017 17:16 | ............and I wouldn't blame you. A reasoned opinion is one thing but claiming special inside knowledge is another and if the only source you can give is a 'casual observer' then IMO it's not credible. | bermudashorts | |
31/10/2017 17:07 | BoB Not until I saw that in R N S There are far too many trHYPE CLUB FAILURES here to make anyone think anything trHYPE CLUB 'invented' is in any-way 'dependable'. Intelligent folks, long ago, deduced that,with ANY trHYPE CLUB 'words on THEIR street' - One could DEPEND on them being subsequently proved WRONG | the real lozan | |
31/10/2017 16:46 | Lozan, I have no problem whatsoever with anyone stating an opinion and if I don't agree with it, I'm happy to discuss and explain my reasons why not. Fragma's posts today weren't stating an opinion though, they were suggesting that he had inside info. re. a placing. If I posted that the word on the street from a casual observer was that Scancell had signed a licensing deal and were about to receive £50m, would you find that credible? | bermudashorts | |
31/10/2017 15:24 | The fact that Scancell will need further funding to commence the SCIB1 trial is no secret - indeed, the Company has stated it via RNS and in presentations many times. However, it is less than 3 weeks since the AGM where it was made absolutely clear that they intend to raise funds after the outcome of current discussions on both SCIB2 and Modi1. It's entirely possible that those discussions won't be as fruitful as hoped and that Scancell are forced to go back to the market, but within 3 weeks? Fragma - thanks for posting but you surely can't be surprised that your claims are met with a certain degree of scepticism. Word on the street from a casual observer is hardly credible evidence. | bermudashorts | |
31/10/2017 14:47 | Have no information as to veracity. However at some point Scancell either have to strike a deal or secure funding for trials. Therefore it is entirely plausible that a Placing is in the offing. | nextlink |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions